Figure 8. Deguelin’s in vivo anti-tumor effects in a Hep-2 xenograft model.
Female BALB/c nude mice, 8–10 weeks of age, weighing 22 to 34 g, were acclimatized for 1 week before being injected s.c. with 3.5×106 Hep-2 cells that had been re-suspended in 100 µL of medium. After 5 days when established tumors around 0.3 cm3 in diameter were detected, mice were randomized and divide in two groups. Ten mice per group were orally treated with deguelin (4 mg/kg) on days 1, 3, and 5 of each week for 3 weeks. Control animals received equal volume of saline solution. Tumor size was measured weekly using method mentioned above (A). Mice survival rate were also measured in (B). p<0.05 vs. vehicle control group. Statistical significance was analyzed by ANOVA.